The continuous stream of performance-enhancing doping news plaguing international sport was headlined recently with an acronym that will be new to probably well over 99 percent of the public: TUE — therapeutic use exemptions. Indeed, that newness illustrates the primary problem with TUEs: They are not at all transparent. Without transparency, it is impossible to analyze other likely ethical problems that TUEs raise.
Read the article here.